142 related articles for article (PubMed ID: 27283172)
1. Population-Based BRCA1/2 Testing in Ashkenazi Jews: Ready for Prime Time.
Lynce F; Isaacs C
J Natl Compr Canc Netw; 2016 Jun; 14(6):809-12. PubMed ID: 27283172
[No Abstract] [Full Text] [Related]
2. Population-based BRCA1/BRCA2 screening in Ashkenazi Jews: a call for evidence.
Levy-Lahad E
Genet Med; 2009 Sep; 11(9):620-1. PubMed ID: 19690506
[No Abstract] [Full Text] [Related]
3. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
[TBL] [Abstract][Full Text] [Related]
4. Incidence of BRCA1 and BRCA2 non-founder mutations in patients of Ashkenazi Jewish ancestry.
Rosenthal E; Moyes K; Arnell C; Evans B; Wenstrup RJ
Breast Cancer Res Treat; 2015 Jan; 149(1):223-7. PubMed ID: 25476495
[TBL] [Abstract][Full Text] [Related]
5. [BRCAmutations more frequent in people of Jewish ancestry].
Menko FH; Rosenberg EH; van der Kolk LE
Ned Tijdschr Geneeskd; 2019 Mar; 163():. PubMed ID: 30875152
[TBL] [Abstract][Full Text] [Related]
6. Precision medicine meets public health: population screening for BRCA1 and BRCA2.
Levy-Lahad E; Lahad A; King MC
J Natl Cancer Inst; 2015 Jan; 107(1):420. PubMed ID: 25550384
[No Abstract] [Full Text] [Related]
7. Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families.
Stadler ZK; Saloustros E; Hansen NA; Schluger AE; Kauff ND; Offit K; Robson ME
Breast Cancer Res Treat; 2010 Sep; 123(2):581-5. PubMed ID: 20221693
[TBL] [Abstract][Full Text] [Related]
8. Cancer risk in Jewish BRCA1 and BRCA2 mutation carriers: effects of oral contraceptive use and parental origin of mutation.
Bernholtz S; Laitman Y; Kaufman B; Paluch Shimon S; Friedman E
Breast Cancer Res Treat; 2011 Sep; 129(2):557-63. PubMed ID: 21499684
[TBL] [Abstract][Full Text] [Related]
9. Risk-reducing surgery in BRCA 1/2 mutation carries: a point of view.
De Felice F; Marchetti C
Oncotarget; 2015 Nov; 6(37):39391-2. PubMed ID: 26588056
[No Abstract] [Full Text] [Related]
10. Two BRCA1/2 founder mutations in Jews of Sephardic origin.
Sagi M; Eilat A; Ben Avi L; Goldberg Y; Bercovich D; Hamburger T; Peretz T; Lerer I
Fam Cancer; 2011 Mar; 10(1):59-63. PubMed ID: 21063910
[TBL] [Abstract][Full Text] [Related]
11. Two patients with germline mutations in both BRCA1 and BRCA2 discovered unintentionally: a case series and discussion of BRCA testing modalities.
Augustyn AM; Agostino NM; Namey TL; Nair S; Martino MA
Breast Cancer Res Treat; 2011 Sep; 129(2):629-34. PubMed ID: 21607582
[TBL] [Abstract][Full Text] [Related]
12. Unknown significance.
Couzin-Frankel J
Science; 2014 Dec; 346(6214):1167-70. PubMed ID: 25477439
[No Abstract] [Full Text] [Related]
13. Sensitivity of BRCA1/2 mutation testing in 466 breast/ovarian cancer families.
Evans DG; Bulman M; Young K; Gokhale D; Lalloo F
J Med Genet; 2003 Sep; 40(9):e107. PubMed ID: 12960223
[No Abstract] [Full Text] [Related]
14. Log odds of carrying an Ancestral Mutation in BRCA1 or BRCA2 for a Defined personal and family history in an Ashkenazi Jewish woman (LAMBDA).
Apicella C; Andrews L; Hodgson SV; Fisher SA; Lewis CM; Solomon E; Tucker K; Friedlander M; Bankier A; Southey MC; Venter DJ; Hopper JL
Breast Cancer Res; 2003; 5(6):R206-16. PubMed ID: 14580256
[TBL] [Abstract][Full Text] [Related]
15. MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent.
Yarden RI; Friedman E; Metsuyanim S; Olender T; Ben-Asher E; Papa MZ
Breast Cancer Res Treat; 2008 Oct; 111(3):497-504. PubMed ID: 18026875
[TBL] [Abstract][Full Text] [Related]
16. The yield of full BRCA1/2 genotyping in Israeli high-risk breast/ovarian cancer patients who do not carry the predominant mutations.
Barnes-Kedar I; Bernstein-Molho R; Ginzach N; Hartmajer S; Shapira T; Magal N; Kalis ML; Peretz T; Shohat M; Basel-Salmon L; Friedman E; Bazak L; Goldberg Y
Breast Cancer Res Treat; 2018 Nov; 172(1):151-157. PubMed ID: 30014164
[TBL] [Abstract][Full Text] [Related]
17. Preventive surgery is associated with reduced cancer risk and mortality in women with BRCA1 and BRCA2 mutations.
Domchek SM; Rebbeck TR
LDI Issue Brief; 2010; 16(2):1-4. PubMed ID: 21545057
[TBL] [Abstract][Full Text] [Related]
18. A family with three germline mutations in BRCA1 and BRCA2.
Liede A; Metcalfe K; Offit K; Brown K; Miller S; Narod SA; Moslehi R
Clin Genet; 1998 Sep; 54(3):215-8. PubMed ID: 9788724
[TBL] [Abstract][Full Text] [Related]
19. Genetic testing for hereditary breast and ovarian cancer and the USPSTF recommendations.
Wood ME; Garber JE; Isaacs C; Masood S; Bedrosian I; Tung N; Chun J; Schnabel FR; Arun BK;
Breast J; 2019 Jul; 25(4):575-577. PubMed ID: 31280501
[No Abstract] [Full Text] [Related]
20. Familial communication and cascade testing among relatives of BRCA population screening participants.
Lieberman S; Lahad A; Tomer A; Koka S; BenUziyahu M; Raz A; Levy-Lahad E
Genet Med; 2018 Nov; 20(11):1446-1454. PubMed ID: 29595811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]